Recombinant Polypeptide Chromatography to Reduce Hamster PLBL2
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing purification methods for recombinant polypeptides produced in Chinese hamster ovary (CHO) cells fail to effectively reduce the levels of hamster PLBL2, a host cell protein that can lead to immunogenicity when administered to humans.
Innovation Solution
A multi-step purification process involving hydrophobic interaction chromatography (HIC), protein A affinity chromatography, and anion exchange chromatography is employed to achieve significantly reduced levels of hamster PLBL2 in recombinant polypeptides, particularly anti-IL13 antibodies, ensuring purity suitable for human therapeutic use.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If conventional purification methods are used for recombinant polypeptides produced in CHO cells, then the purification process is simple and fast, but the levels of hamster PLBL2 (a host cell protein) remain high causing immunogenicity
Solution Approach 1:
The purification process is divided into multiple sequential chromatography steps, each targeting specific impurities. The process segments the removal of different host cell proteins (including PLBL2) and other contaminants through distinct purification stages: capture chromatography, intermediate purification, and polishing steps, thereby achieving comprehensive removal of immunogenic impurities
Solution Approach 2:
The patent employs intermediate buffer solutions and transition steps between chromatography stages to facilitate the removal of PLBL2. These intermediary steps include specific buffer compositions and pH adjustments that enable effective separation of PLBL2 from the recombinant polypeptide without causing denaturation or loss of activity
2Manufacturing precision
If conventional purification methods are used, then the process is quick and efficient, but the purity of recombinant polypeptide is insufficient for human therapeutic use
Solution Approach 1:
The purification process begins with a capture step that preliminarily concentrates the recombinant polypeptide and removes bulk impurities before subsequent refinement steps. This preliminary action prepares the sample for more precise purification steps, ensuring high purity is achieved efficiently through staged processing rather than attempting single-step purification
Solution Approach 2:
The patent utilizes changes in pH, ionic strength, and temperature parameters across different chromatography steps to optimize separation efficiency. Each chromatography stage employs specific parameter conditions that maximize the resolution between recombinant polypeptide and host cell proteins, achieving high purity while maintaining reasonable processing speed
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The process results in recombinant polypeptides with substantially reduced hamster PLBL2 levels, enhancing their safety and efficacy as human therapeutics by minimizing immunogenicity.
Implementation Method 1
hydrophobic interaction chromatography (HIC)
Implementation Method 2
protein A affinity chromatography
Implementation Method 3
anion exchange chromatography
Data Source
AI summary
Purified recombinant polypeptides isolated from Chinese hamster ovary host cells, including antibodies, such as therapeutic antibodies, and methods of making and using such polypeptides are provided.